文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

解码危重患者念珠菌血症:无监督聚类识别三种独特表型

Decoding candidemia in critically ill patients: unsupervised clustering identifies three unique phenotypes.
PubMed 文献 · Crit Care · 2026-06-28
一句话结论多中心回顾性队列显示,ICU念珠菌血症可分三种表型,90天死亡率分别为72.9%、70.4%和50.3%,肝硬化和高龄与死亡相关,导管相关感染具保护作用。

该多中心回顾性队列纳入法国16个ICU的492例念珠菌血症患者(2015-2023年),采用混合数据因子分析(FAMD)结合主成分层次聚类(HCPC)识别表型。共识别三种表型:表型1(n=70,14.2%)为严重免疫抑制(82.9%为血液恶性肿瘤)且SAPS II评分高(70);表型2(n=223,45.3%)为老年肝硬化(19.3%)伴早发性消化道念珠菌血症;表型3(n=199,40.5%)为较年轻、严重程度评分较低且导管相关念珠菌血症。90天总死亡率为62.6%,三种表型死亡率分别为72.9%、70.4%和50.3%(p<0.001)。多因素分析显示年龄、肝硬化、SAPS II评分与死亡独立相关,棘白菌素使用和证实为导管相关感染为保护因素,免疫抑制与死亡无关。

要点

  • 492例ICU念珠菌血症患者中,90天总死亡率为62.6%,三种表型死亡率分别为72.9%(表型1)、70.4%(表型2)和50.3%(表型3)(p<0.001)。
  • 表型1(n=70,14.2%)特征为严重免疫抑制(82.9%为血液恶性肿瘤)且SAPS II评分高(70),90天死亡率72.9%。
  • 表型2(n=223,45.3%)特征为老年肝硬化(19.3%)伴早发性消化道念珠菌血症,90天死亡率70.4%。
  • 表型3(n=199,40.5%)特征为较年轻、严重程度评分较低且导管相关念珠菌血症,90天死亡率50.3%。
  • 多因素分析:年龄(aHR 1.01,95%CI 1.00-1.02)、肝硬化(aHR 1.90,95%CI 1.39-2.60)和SAPS II(aHR 1.01,95%CI 1.01-1.02)与死亡独立相关;棘白菌素使用(aHR 0.49,95%CI 0.39-0.63)和证实导管相关感染(aHR 0.48,95%CI 0.33-0.69)为保护因素;免疫抑制与死亡无关。

适用人群与场景

  • 法国16个ICU的492例念珠菌血症患者,年龄中位数64岁,男性69.1%,研究期间2015-2023年。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入492例ICU念珠菌血症患者,采用FAMD结合HCPC识别出三种表型。
  • 表型1(n=70,14.2%):严重免疫抑制,82.9%为血液恶性肿瘤,SAPS II评分70,90天死亡率72.9%。
  • 表型2(n=223,45.3%):老年肝硬化患者(19.3%)伴早发性消化道念珠菌血症,90天死亡率70.4%。
  • 表型3(n=199,40.5%):较年轻患者,严重程度评分较低,导管相关念珠菌血症,90天死亡率50.3%。
  • 三种表型90天死亡率差异显著(p<0.001)。
  • 多因素分析:年龄(aHR 1.01,95%CI 1.00-1.02;p=0.003)、肝硬化(aHR 1.90,95%CI 1.39-2.60;p<0.001)、SAPS II(aHR 1.01,95%CI 1.01-1.02;p<0.001)与死亡独立相关;棘白菌素使用(aHR 0.49,95%CI 0.39-0.63;p<0.001)和证实导管相关念珠菌血症(保护性;aHR 0.48,95%CI 0.33-0.69;p<0.001)与死亡独立相关;免疫抑制与死亡无关。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,无监督聚类识别出三种临床不同的念珠菌血症表型且结局不同;肝硬化、较高年龄和疾病严重程度与死亡相关,而导管相关感染源具有保护作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Candidemia displays significant clinical heterogeneity in critically ill patients. This study aimed to identify distinct clinical phenotypes and to assess their association with 90-day mortality.

METHODS: We conducted a multicenter retrospective cohort study of 492 intensive care unit (ICU) patients with candidemia from 16 French ICUs (2015-2023). We performed a factor analysis of mixed data (FAMD) incorporating both categorical and continuous baseline variables, followed by hierarchical clustering on principal components (HCPC). Survival analysis was performed with Kaplan-Meier curves and Cox proportional hazards models.

RESULTS: Overall, 90-day mortality for the 492 patients (median age: 64 years, 69.1% male) with candidemia was 62.6%. Three different phenotypes emerged from FAMD followed by HCPC: Phenotype 1 (n = 70, 14.2%) comprised patients with severe immunosuppression, mostly due to hematological malignancies (82.9%), and high severity scores (SAPS II:70); Phenotype 2 (n = 223, 45.3%) corresponded to elderly cirrhotic patients (19.3%) with early-onset digestive candidemia; Phenotype 3 (n = 199, 40.5%) comprised younger patients with lower severity scores and catheter-related candidemia. Mortality differed significantly between phenotypes: 72.9% (Phenotype 1), 70.4% (Phenotype 2), and 50.3% (Phenotype 3) (p < 0.001). Independent predictors of mortality included age (aHR: 1.01, 95% CI: 1.00-1.02; p = 0.003), cirrhosis (aHR: 1.90, 95% CI: 1.39-2.60; p < 0.001), SAPS II (aHR: 1.01, 95% CI: 1.01-1.02; p < 0.001), echinocandin use (aHR = 0.49, 95% CI: 0.39-0.63; p < 0.001) and proven catheter-related candidemia (protective; aHR: 0.48, 95% CI: 0.33-0.69; p < 0.001). Immunodepression was not associated with mortality.

CONCLUSION: Unsupervised clustering identified three clinically different candidemia phenotypes with different outcomes. Cirrhosis, higher age and illness severity were associated with mortality, whereas a catheter-related source of infection was protective.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reizine F, Henry J, Desmedt L, et al. Decoding candidemia in critically ill patients: unsupervised clustering identifies three unique phenotypes. Crit Care. 2026. PMID: 42365321. doi:10.1186/s13054-026-05964-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。